
A phase 3 trial has found that SB15, a biosimilar of aflibercept, demonstrates equivalent efficacy and comparable safety, pharmacokinetics, and immunogenicity to the reference aflibercept in patients with neovascular age-related macular degeneration (nAMD). The study, conducted at multiple centers across 10 countries, included 449 participants who were randomly assigned to receive either SB15 or aflibercept. The results showed similar improvements in best-corrected visual acuity and central subfield thickness between the two groups up to week 32. The findings suggest that aflibercept biosimilars like SB15 have the potential to expand treatment options and enhance patient access to effective therapy for retinal diseases.
Like
Save
Share